CDK1 and neoplasm: The results showed that HCT8‐OR and HT29‐OR‐bearing mice did not respond to oxaliplatin; however, when CDK1 was knocked out, the tumor mass was significantly reduced following oxaliplatin treatment, which was further verified by IHC staining of the Ki‐67 (a proliferation marker) (Figure 2M–R).